Search "can Medicare patients use patient assistance programs" and you'll get a flat "no" from some sources and a flat "yes" from others — and both are half-right. The honest answer requires separating two things that get lumped together under the same name: programs run directly by the company that makes the drug, and programs run by independent nonprofits that happen to receive some manufacturer funding. Federal regulators treat these completely differently, and that difference is the entire answer to this question. Here's the actual legal logic, what it means for your out-of-pocket costs, and a regulatory deadline at the end of 2026 worth keeping an eye on.
1. Why Manufacturer PAPs Exclude Medicare Patients
The reason traces back to a specific piece of federal law: the Anti-Kickback Statute. It prohibits offering anything of value intended to induce a Medicare beneficiary's use of a particular drug, provider, or service. In November 2005, right before Medicare Part D launched, the HHS Office of Inspector General issued a Special Advisory Bulletin addressing exactly this scenario: could drug manufacturers keep subsidizing Part D cost-sharing through their own PAPs?
OIG's answer was clear: manufacturer PAPs that subsidize a Medicare beneficiary's cost-sharing for that same manufacturer's drug present heightened risk under the Anti-Kickback Statute. The concern is straightforward — a company covering your copay for its own product can function as an inducement to keep using that product, and it can mask the drug's real price from the market and from Medicare's own cost calculations.
That 2005 guidance is why, two decades later, nearly every manufacturer PAP — including the ones for Ozempic, Mounjaro, and most other brand-name drugs — explicitly excludes Medicare Part D beneficiaries in its eligibility rules, regardless of income.
2. The Exception: Independent Charity PAPs
The same 2005 bulletin drew a sharp distinction for a different structure: assistance from a truly independent charity. OIG concluded that cost-sharing help from a genuinely independent nonprofit doesn't raise the same concerns — even when that charity accepts donations from drug manufacturers — as long as the charity, not the donor, controls how the money is used.
| Requirement | Why it matters |
|---|---|
| Donors don't control which diseases get funded | Prevents a manufacturer from steering money only toward conditions treated by its own drugs |
| Assistance isn't limited to one manufacturer's drug | A qualifying disease fund typically must cover all drugs used to treat that condition, not just one brand |
| No patient-level reporting back to donors | Keeps the manufacturer from knowing which of its own patients received help |
| Registered 501(c)(3) nonprofit status | Establishes the organization as legally and financially separate from its donors |
Organizations like the Patient Advocate Foundation (which merged with the PAN Foundation in March 2026) and the HealthWell Foundation are structured specifically around meeting these independence rules, which is why they can serve Medicare beneficiaries where a manufacturer's own PAP cannot.
3. Manufacturer PAP vs. Independent Charity PAP for Medicare
| Factor | Manufacturer PAP | Independent Charity PAP |
|---|---|---|
| Medicare Part D beneficiaries eligible? | No, generally excluded | Yes, if income/disease criteria met |
| Run by | The drug's manufacturer | An independent 501(c)(3) nonprofit |
| Funding source | The manufacturer directly | May include manufacturer donations, but donors don't control fund criteria |
| Drug coverage | Only that manufacturer's specific brand | Typically covers all drugs used to treat a qualifying condition |
| Counts toward Part D TrOOP? | Generally no | Generally yes |
4. Does This Count Toward Your Part D Out-of-Pocket Cap?
This is the detail most explanations skip entirely, and it materially affects how much you benefit from each type of program.
True out-of-pocket (TrOOP) is the running total that determines when you've paid enough during the year to reach Part D's catastrophic out-of-pocket cap. Payments made on your behalf by a qualifying independent charity generally count toward that total — the same way a payment from a family member or a qualifying State Pharmaceutical Assistance Program does. Manufacturer PAP assistance, by contrast, is typically structured to sit outside your Part D benefit entirely, which means it usually doesn't count toward TrOOP at all.
In practice, that means a Medicare beneficiary getting $2,000 of copay help from an independent charity this year is $2,000 closer to hitting the annual out-of-pocket cap, on top of not having paid that money themselves. A beneficiary who somehow received the same amount through a manufacturer PAP wouldn't get that second benefit — though as covered above, most Medicare beneficiaries can't access manufacturer PAPs for their Part D drugs regardless.
5. The 2026-2027 Regulatory Landscape
This area of law isn't static, and two current developments are worth understanding if you're relying on charity assistance going forward.
| Development | What it means |
|---|---|
| OIG Advisory Opinion sunset clause | A February 2026 favorable OIG opinion permitting a specific charity's disease-fund structure is explicitly limited to expire December 31, 2026 — OIG tied this directly to the Part D out-of-pocket cap potentially changing its risk analysis |
| Litigation over "coalition model" charities | At least one narrowly-funded, manufacturer-coalition charity has challenged an unfavorable OIG opinion in court, signaling active regulatory tension around less-independent charity structures |
Why the out-of-pocket cap matters to regulators here: Medicare Part D's out-of-pocket cap fully phased in and has adjusted annually since 2024, capping most beneficiaries' total drug costs for the year. OIG has explicitly said that lower beneficiary cost-sharing changes the fraud-and-abuse calculus around charity assistance — with beneficiaries already facing a capped maximum cost, the argument for needing manufacturer-adjacent charity help looks different than it did before the cap existed. Expect updated guidance around this area heading into 2027.
6. What to Check Before Applying to a Charity PAP
Charity assistance shouldn't be your first stop if you're on Medicare — it's usually the backup option after the government's own programs.
| Program | Why check it before a charity PAP |
|---|---|
| Extra Help (Part D Low-Income Subsidy) | Directly caps your Part D copays and deductible if you qualify by income — often resolves the problem outright |
| Your state's Pharmaceutical Assistance Program | Some states offer their own drug cost help for Medicare beneficiaries, and qualifying assistance also counts toward TrOOP |
| Your Part D plan's exceptions process | If your drug is on a high formulary tier, a formulary exception can sometimes lower your cost-sharing directly |
7. Step-by-Step: How a Medicare Patient Applies
Confirm you don't qualify for Extra Help first
Check your income against the current Extra Help limits before applying elsewhere, since it's the simplest fix if you qualify.
Search by your specific diagnosis, not the drug name
Independent charity funds are typically organized by disease category, so search "[your condition] copay assistance" rather than the brand name of your medication.
Confirm the fund is currently open
Disease funds run on limited annual money and can close to new applicants once fully allocated — check current status directly on the charity's site before applying.
Submit income and diagnosis documentation
Most applications require proof of Medicare enrollment, income documentation, and confirmation of your diagnosis from your prescriber.
Ask your pharmacy how the assistance will be applied
Confirm with your pharmacist that the charity payment will be reported correctly so it counts toward your Part D out-of-pocket total for the year.
8. Red Flags: Spotting a Charity That Isn't Really Independent
Signs of Genuine Independence
- Diversified funding from many donors across the industry, not one or two manufacturers
- Disease funds cover every drug used to treat that condition, not one brand
- Long operating history and transparent public financial disclosures
- No requirement to use a specific pharmacy or provider tied to a donor
Warning Signs
- Funded almost entirely by a small "coalition" of manufacturers in one drug category
- Disease fund criteria that happen to match only one or two specific brand-name drugs
- Recently formed, with limited public financial history
- Any requirement to fill at a specific pharmacy connected to a donor manufacturer
9. Decision Tree: What Should You Do?
Check Patient Advocate Foundation and HealthWell Foundation for an open disease fund matching your condition — this is the legitimate path for Medicare patients.